ES2377489T3 - Péptido derivado del receptor 3 de neurotensina y utilización en el tratamiento de enfermedades psiquiátricas - Google Patents

Péptido derivado del receptor 3 de neurotensina y utilización en el tratamiento de enfermedades psiquiátricas Download PDF

Info

Publication number
ES2377489T3
ES2377489T3 ES08872504T ES08872504T ES2377489T3 ES 2377489 T3 ES2377489 T3 ES 2377489T3 ES 08872504 T ES08872504 T ES 08872504T ES 08872504 T ES08872504 T ES 08872504T ES 2377489 T3 ES2377489 T3 ES 2377489T3
Authority
ES
Spain
Prior art keywords
peptide
trek
mice
depression
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08872504T
Other languages
English (en)
Spanish (es)
Inventor
Jean Mazella
Olivier Petrault
Marc Borsotto
Catherine Heurteaux
Catherine Widmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Université Côte d'Azur
Original Assignee
Centre National de la Recherche Scientifique
Université Côte d'Azur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Université Côte d'Azur filed Critical Centre National de la Recherche Scientifique
Application granted granted Critical
Publication of ES2377489T3 publication Critical patent/ES2377489T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES08872504T 2007-12-21 2008-12-18 Péptido derivado del receptor 3 de neurotensina y utilización en el tratamiento de enfermedades psiquiátricas Active ES2377489T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07291602 2007-12-21
EP07291602A EP2077278A1 (fr) 2007-12-21 2007-12-21 Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques
PCT/FR2008/001784 WO2009103898A1 (fr) 2007-12-21 2008-12-18 Peptide derive du recepteur 3 de la neurotensine et utilisation dans le traitement de maladies psychiatriques

Publications (1)

Publication Number Publication Date
ES2377489T3 true ES2377489T3 (es) 2012-03-28

Family

ID=39304741

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08872504T Active ES2377489T3 (es) 2007-12-21 2008-12-18 Péptido derivado del receptor 3 de neurotensina y utilización en el tratamiento de enfermedades psiquiátricas

Country Status (7)

Country Link
US (1) US8252748B2 (enExample)
EP (2) EP2077278A1 (enExample)
JP (1) JP5487117B2 (enExample)
AT (1) ATE535543T1 (enExample)
CA (1) CA2709907C (enExample)
ES (1) ES2377489T3 (enExample)
WO (1) WO2009103898A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2077278A1 (fr) * 2007-12-21 2009-07-08 Centre National de la Recherche Scientifique (CNRS) Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques
CA2938019A1 (en) * 2014-01-27 2015-07-30 Centre National De La Recherche Scientifique Retro-inverso analogs of spadin display increased antidepressant effects
PT3380495T (pt) 2015-11-24 2021-08-19 Transfert Plus Sec Compostos peptídicos e conjugados peptídicos para o tratamento de cancro através de quimioterapia mediada por recetores
FR3057267A1 (fr) 2016-10-11 2018-04-13 Centre National De La Recherche Scientifique - Cnrs - Procede de diagnostic/determination de l'efficacite de traitement de la depression
FR3057266B1 (fr) * 2016-10-11 2021-05-21 Centre Nat Rech Scient Peptides derives du propeptide ntsr3 et leur utilisation dans le traitement de la depression
US12662512B2 (en) 2019-10-22 2026-06-23 Genethon Chimeric polypeptides and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037762A1 (en) * 1998-01-27 1999-07-29 Smithkline Beecham Plc Trek-1 like two pore potassium channel
DK1891966T3 (da) * 2002-12-20 2012-04-02 Lundbeck & Co As H Modulation af neurotrophinaktivitet; fremgangsmåde til screening
EP2077278A1 (fr) 2007-12-21 2009-07-08 Centre National de la Recherche Scientifique (CNRS) Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques

Also Published As

Publication number Publication date
US20110237515A1 (en) 2011-09-29
JP2011505864A (ja) 2011-03-03
CA2709907A1 (fr) 2009-08-27
EP2229408B1 (fr) 2011-11-30
US8252748B2 (en) 2012-08-28
EP2077278A1 (fr) 2009-07-08
WO2009103898A1 (fr) 2009-08-27
CA2709907C (fr) 2016-11-08
EP2229408A1 (fr) 2010-09-22
ATE535543T1 (de) 2011-12-15
JP5487117B2 (ja) 2014-05-07

Similar Documents

Publication Publication Date Title
JP7693290B2 (ja) Ｌａｒファミリーホスファターゼの活性を阻害する組成物及び方法
Odaira et al. Mechanisms underpinning AMP-activated protein kinase-related effects on behavior and hippocampal neurogenesis in an animal model of depression
ES2813629T3 (es) Compuestos de TAFA4 y usos de los mismos para tratar el dolor
AU2016215080B2 (en) Methods and compositions for improved cognition
US20250163126A1 (en) Artificial synapses
ES2745335T3 (es) Proteínas de fusión TATk-CDKL5, composiciones, formulaciones y uso de estas
Cheng et al. Transcranial direct-current stimulation protects against cerebral ischemia-reperfusion injury through regulating Cezanne-dependent signaling
US8252748B2 (en) Peptide derived from neurotensin receptor 3 and use thereof in the treatment of psychiatric diseases
JP2020023508A (ja) ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す
JP2017507655A5 (enExample)
CN115006534A (zh) 钾离子通道Kir4.1抑制剂治疗抑郁症的用途和药物组合物
CN101454341B (zh) 表面核仁素的多价合成配体在治疗癌症或发炎中的用途
JP2019522989A (ja) ＴＡＴκ−ＣＤＫＬ５融合タンパク質、組成物、製剤、及びそれらの使用
ES2186596T3 (es) Uso de inhibidores de la interleucina-18 para inhibir metastasis tumorales.
ES2617309T3 (es) Métodos y ensayos de tratamiento de sujetos con eliminación, mutación o expresión reducida de SHANK3
ES2569552T3 (es) Composiciones de péptido de MNTF y métodos de uso
ES2320862T3 (es) Proteina de fusion.
ES2524564T3 (es) Identificación de nuevas toxinas antagonistas de canales de calcio de tipo T de aplicación analgésica
ES2677564T3 (es) Método y composición farmacéutica para su uso en el tratamiento de trastornos neurodegenerativos
US8481486B2 (en) Methods of treating neurological diseases by regulating migration of neuroblasts in the adult nervous system with tenascin-R
ES2965080T3 (es) Péptidos derivados del propéptido NTSR3 y su uso en el tratamiento de la depresión
US20110189194A1 (en) Use of cd95 inhibitors for the treatment of inflammatory disorders
US9012407B2 (en) Therapies which act on neuropeptide S receptors
Yoon et al. Shifting hippocampal excitation/inhibition balance modifies despair-like behavior in mice
WO2026056985A1 (zh) 抑郁症的治疗方法和药物组合物